Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...

Inborn Errors of Metabolism

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...

Genetic Screens

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Brain morphometry and cognition in late-onset glutaric aciduria type 1: scoping review and novel insights from a case report.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026

Same author

Long-term safety outcomes and patient preferences for home-based intravenous enzyme replacement therapy (ERT) in Pompe disease and Mucopolysaccharidosis Type I (MPS-I): final results of two-year observation.

Orphanet journal of rare diseases·2025

Same author

Non-neurological, non-skeletal outcomes after hematopoietic stem and progenitor cell-gene therapy (OTL-203) for Hurler syndrome.

Molecular therapy : the journal of the American Society of Gene Therapy·2025

Same author

Long-term enzyme replacement therapy: Findings from the mucopolysaccharidosis VI clinical surveillance program after 15 years follow-up.

Molecular genetics and metabolism·2025

Same author

A new approach to study stochastic epigenetic mutations in sperm methylome of Vietnam war veterans directly exposed to Agent Orange.

Environmental epigenetics·2024

Same author

Early skeletal outcomes after hematopoietic stem and progenitor cell gene therapy for Hurler syndrome.

Science translational medicine·2024

Search research articles

Related Experiment Video

Updated: May 30, 2026

One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure

One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure

Published on: June 25, 2010

Metabolic screening for the newborn.

Rossella Parini¹, Carlo Corbetta

¹Rare Metabolic Diseases Unit, Pediatric Clinic, San Gerardo Hospital, University Milano Bicocca, Monza, Italy. rossella.parini@unimib.it

The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians

|October 5, 2011

Summary

This summary is machine-generated.

Tandem mass spectrometry (MS/MS) has expanded newborn screening for metabolic diseases. However, optimal screening strategies and demonstrating long-term benefits remain challenging, requiring careful analysis of regional program results.

More Related Videos

Biochemical Measurement of Neonatal Hypoxia

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

Non-invasive Optical Measurement of Cerebral Metabolism and Hemodynamics in Infants

Non-invasive Optical Measurement of Cerebral Metabolism and Hemodynamics in Infants

Published on: March 14, 2013

Related Experiment Videos

Last Updated: May 30, 2026

One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure

One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure

Published on: June 25, 2010

Biochemical Measurement of Neonatal Hypoxia

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

Non-invasive Optical Measurement of Cerebral Metabolism and Hemodynamics in Infants

Non-invasive Optical Measurement of Cerebral Metabolism and Hemodynamics in Infants

Published on: March 14, 2013

Area of Science:

Biochemistry
Medical Genetics
Public Health

Background:

Tandem mass spectrometry (MS/MS) has significantly advanced the detection of metabolic diseases.
Newborn screening programs vary globally in scope, from detecting numerous conditions (USA) to a limited few (Germany, UK, Switzerland).
Demonstrating the statistical benefit of neonatal screening for metabolic disorders is complex due to disease characteristics.

Purpose of the Study:

To review the impact and variations in newborn screening practices using MS/MS.
To discuss the challenges in implementing and evaluating expanded newborn screening programs.
To highlight the need for continued data collection and analysis for optimizing screening strategies.

Main Methods:

Review of current practices in newborn screening using tandem mass spectrometry.
Analysis of different national policies regarding the scope of detected metabolic diseases.
Discussion of the clinical and epidemiological challenges in assessing screening efficacy.

Main Results:

MS/MS enables rapid detection of a wide spectrum of metabolic disorders.
Significant differences exist in the number of conditions screened across countries.
Expanded screening includes conditions with uncertain significance and varying clinical presentations, complicating benefit assessment.

Conclusions:

Optimizing newborn screening requires careful collection and analysis of regional program data.
Standardized approaches may not be suitable for all countries due to differing healthcare systems and disease prevalences.
Future efforts should focus on refining screening protocols and extending programs to developing countries.